Neuroendocrine tumors (NETs) are a rare and complex form of cancer that arises from the neuroendocrine cells, which are scattered throughout the body and release hormones into the bloodstream. These tumors can occur anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The incidence of NETs has been increasing in recent years, and they are now recognized as a significant health burden worldwide. The neuroendocrine tumor treatment market is a rapidly evolving field, with new therapies and treatment options being developed to address the needs of patients.
The global neuroendocrine tumor treatment market is expected to reach $2.6 billion by 2027, with a compound annual growth rate (CAGR) of 10.2% from 2020 to 2027.